神经外科医疗服务

Search documents
三博脑科盘中波动明显 早盘快速反弹后回调
Sou Hu Cai Jing· 2025-08-15 20:59
截至2025年8月15日15时29分,三博脑科股价报66.46元,较前一交易日下跌1.36元。当日开盘价为67.48 元,最高触及69.80元,最低下探65.71元,成交量为33.25万手,成交金额达22.32亿元。 来源:金融界 三博脑科主营业务为神经外科医疗服务,涉及精准医疗等领域。公司总市值136.90亿元,流通市值 106.96亿元。 从资金流向来看,8月15日主力资金净流出2.11亿元,近五日累计净流出1.81亿元。早盘交易时段,该股 曾出现快速波动,9点36分出现超过2%的快速回调,9点52分又出现超过2%的快速反弹。 风险提示:股市有风险,投资需谨慎。 ...
三博脑科股价上涨4.82% 成交额突破19.95亿元
Sou Hu Cai Jing· 2025-08-12 10:05
Core Viewpoint - Sanbo Brain Science's stock price increased by 4.82% on August 12, 2025, indicating strong market interest and activity in the neuro-surgery sector [1] Company Summary - Sanbo Brain Science's stock closed at 60.18 yuan, with a daily high of 62.57 yuan and a low of 56.71 yuan, resulting in a trading range of 10.21% [1] - The company specializes in neuro-surgery medical services, including diagnosis, surgery, and rehabilitation for brain diseases [1] - The stock is part of sectors such as medical services and precision medicine [1] Market Activity - The stock experienced a rapid rebound in the morning session, with a gain of over 2% within the first five minutes of trading [1] - The overall performance of brain-computer interface concept stocks was active, contributing to the rise of related stocks [1] - On August 12, the net outflow of main funds was 394.94 thousand yuan, accounting for 0.04% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow of main funds reached 31.2 million yuan, representing 3.22% of the circulating market value [1]
三博脑科(301293) - 301293三博脑科投资者关系管理信息20250512
2025-05-12 09:34
Group 1: Financial Performance - In Q1 2025, the company achieved revenue of ¥393,473,847.68, a year-on-year increase of 16.78% [4] - The net profit attributable to shareholders was ¥38,313,576.61, reflecting a year-on-year growth of 14.56% [4] - After deducting non-recurring gains and losses, the net profit attributable to shareholders was ¥38,606,346.69, with a year-on-year increase of 19.40% [4] Group 2: Industry Outlook - The medical industry in China is experiencing high-quality development driven by policy support and technological innovation [5] - Private hospitals are expected to alleviate pressure on public hospitals and provide diverse medical services, enhancing overall healthcare resource allocation [5] - Specialized hospitals are crucial for the advancement of medical science and improving healthcare quality [5] Group 3: Expansion Plans - The Beijing Sanbo Dongba new hospital project is on track to be completed by March 2026, which will enhance service capacity [6] - The Kunming Sanbo new hospital has completed site acceptance and is in the process of relocation [6] - The Xi'an Sanbo new hospital is undergoing various acceptance procedures and is expected to open in Q3 2025 [6] Group 4: Regulatory and Compliance Issues - The company maintains a commitment to compliance and has not identified any illegal activities involving its executives [10] - The chairman's recent detention is attributed to personal reasons and is not related to the company [10] - The company has established a governance structure to ensure stable operations during this period [10] Group 5: Market Challenges - The impact of medical insurance policies and procurement practices is expected to reduce income, but the company is working to enhance bed turnover and service volume [3] - The company is also integrating its supply chain to lower procurement costs and mitigate the effects of insurance policies on profits [3] - The competitive landscape in the medical service market is intensifying, affecting revenue growth [11]